References
- Kahan, B. D., Therapeutic drug monitoring of cyclosporine: 20 years of progress, Transplant. Proc., 36, 378S-391S (2004). https://doi.org/10.1016/j.transproceed.2004.01.091
- Hardinger, K.L., Koch, M.J. and Brennan, D.C., Current and future immunosuppressive strategies in renal transplantation, Pharmacotherapy, 24, 1159-1176 (2004). https://doi.org/10.1592/phco.24.13.1159.38094
- Magnasco, A., Rossi, A., Catarsi, P., Gusmano, R., Ginevri, F., Perfumo, F. and Ghiggeri, G.M., Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives, Curr. Clin. Pharmacol., 3, 166-173 (2008). https://doi.org/10.2174/157488408785747674
- Watts, A.B. and Williams, R.O., 3rd, Peters JI, Recent developments in drug delivery to prolong allograft survival in lung transplant patients, Drug Dev. Ind. Pharm., 1-13 (2008)
- Ritschel, W.A., Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral, Clin. Transplant., 10, 364-373 (1996).
- Andrysek, T., Impact of physical properties of formulations on bioavailability of active substance: current and novel drugs with cyclosporine, Mol. Immunol., 39, 1061-1065 (2003). https://doi.org/10.1016/S0161-5890(03)00077-4
- Lawrence, M.J. and Rees, G.D., Microemulsion-based media as novel drug delivery systems, Adv. Drug. Deliv. Rev., 45, 89-121 (2000). https://doi.org/10.1016/S0169-409X(00)00103-4
- Constantinides, P.P., Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects, Pharm. Res., 12, 1561-1572 (1995). https://doi.org/10.1023/A:1016268311867
- Masri, M., The generics in transplantation and the rules on their use, Exp. Clin. Transplant., 1, 65-68 (2003).
- Sharma, A., Shekhar, C., Heer, M. and Minz, M., Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring, Transplant. Proc., 38, 2051-2053 (2006). https://doi.org/10.1016/j.transproceed.2006.07.004
- Al Wakeel, J.S., Shaheen, F.A., Mathew, M.C., Abouzeinab, H.M., Al Alfi, A., Tarif, N.M., Al Mousawi, M.S., Mahmoud, T.S., Alorrayed, A.S., Fagir, E.A., Dham, R.S. and Shaker, D.S., Therapeutic equivalence and mg:mg switch ability of a generic cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients maintained on Sandimmun Neoral, Transplant. Proc., 40, 2252-2257 (2008). https://doi.org/10.1016/j.transproceed.2008.06.043
- Cattaneo, D., Perico, N. and Remuzzi, G., Generic cyclosporine formulations: more open questions than answers, Transpl. Int., 18, 371-378 (2005). https://doi.org/10.1111/j.1432-2277.2005.00078.x
- Ponticelli, C., Generic cyclosporine: a word of caution, J. Nephrol., 17 Suppl 8, S20-24 (2004).
- Johnston, A., Belitsky, P., Frei, U., Horvath, J., Hoyer, P., Helderman, J.H., Oellerich, M., Pollard, S., Riad, H., Rigotti, P., Keown, P. and Nashan, B., Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients, Eur. J. Clin. Pharmacol., 60, 389-395 (2004).
- Hong, C.I., Kim, J.W., Choi, N.H., Shin, H.J. and Yang, S.G., Cyclosporin-containing microemulsion preconcentrate composition, United State Patent, 6063762, (2000).
- Mueller, E.A., Kovarik, J.M., Van Bree, J.B., Grevel, J., Lucker, P.W. and Kutz, K., Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation, Pharm. Res., 11, 151-155 (1994). https://doi.org/10.1023/A:1018922517162
- Yang, S.G., Kim, D.D., Chung, S.J. and Shim, C.K., Stable bioavailability of cyclosporin A, regardless of food intake, from soft gelatin capsules containing a new self-nanoemulsifying formulation, Int. J. Clin. Pharmacol. Ther., 44, 233-239 (2006). https://doi.org/10.5414/CPP44233
- Billaud, E.M., C2 versus C0 cyclosporine monitoring: still not the end, Transplantation, 80, 542-544 (2005). https://doi.org/10.1097/01.tp.0000168101.91087.cb
- Marin, J.G., Levine, M. and Ensom, M.H., Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients?, Ther. Drug. Monit., 28, 637-642 (2006). https://doi.org/10.1097/01.ftd.0000243965.97964.ca
- Midtvedt, K., Therapeutic drug monitoring of cyclosporine, Transplant. Proc., 36, 430S-433S (2004). https://doi.org/10.1016/j.transproceed.2004.01.025